Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 8:31 AM ET

Healthcare Equipment and Supplies

Company Overview of BioCision, LLC

Company Overview

BioCision, LLC develops portable benchtop tools for temperature sensitive biomedical samples for basic and clinical research and diagnostics. It offers cell freezing containers microfuges, storage, portable ice-free cooling/freezing, cool and thermaltrays, ergotubes, accessories, and clinic products. The company’s products are used by researchers in bio-pharma, academic research, clinical research and diagnostics, hospital, government, industry, and medical devices customers. It offers products through distributors in the United States, Canada, Europe, Asia, the Middle East, Australia, and New Zealand; and online. The company was founded in 2007 and is based in Larkspur, California.

12 East Sir Francis Drake Boulevard

Suite B

Larkspur, CA 94939

United States

Founded in 2007





Key Executives for BioCision, LLC

Chief Executive Officer, President and Director
Chief Financial Officer
Vice President of Operations
President of Dark Horse Consulting
Chief Commercialization Officer
Compensation as of Fiscal Year 2015.

BioCision, LLC Key Developments

BioCision Announces FDA Master File Acceptance for ThawSTAR Automated Cell Thawing Instrument

BioCision, LLC announced that the United States Food and Drug Administration (FDA), Center for Devices and Radiological Health, accepted its Device Master File (MAF) submission for the ThawSTAR automated cell thawing system. Utilizing patent-pending STAR™ sensing technology, the ThawSTAR thawing instrument employs multiple detection mechanisms and algorithms to determine vial temperature, phase change initiation and thaw completion, customizing the thaw for each vial containing frozen cellular material. The system’s intuitive, hands-free operation eliminates the guesswork and subjectivity of determining the thawing end point, setting a new bar in thawing reproducibility and making it a necessary component in processes that rely on standardized procedures.

Cook Regentec Selects BioCision, LLC's Proprietary Coolcell Technology

BioCision, LLC announced that they have entered into an exclusive partnership with Cook Regentec to develop two custom CoolCell controlled-rate cell freezing systems for Cook's closed-system cell therapy CellSeal vials. Cook selected BioCision's proprietary CoolCell technology for its effectiveness in standardizing the freezing of cells and cellular therapies such as stem cells and tissue samples that can be used in a wide range of applications from diabetes research to organ transplants. The ease of implementation and use of CoolCell freezing systems, especially as compared to expensive controlled-rate freezers, will provide Cook's CellSeal vial customers a cost-effective, reliable solution for controlled -1 degree Celsius per minute cell freezing, the rate believed to be optimal to ensuring cells remain intact and experience minimal negative effects during the freezing process.

BioCision, LLC to Develop Customized ThawSTAR Automated Cell Thawing System for Celgene Cellular Therapeutics

BioCision, LLC announced that it will collaborate with Celgene Cellular Therapeutics (CCT) to accelerate the development of a cell thawing solution based on BioCision's proprietary ThawSTAR™ technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease. Conventional thawing methods, including swirling vials in warm water baths or rolling vials between hands can result in variable cell viabilities and can increase contamination concerns. BioCision’s ThawSTAR system utilizes a patent pending adaptive sensing technology that incorporates algorithms to deliver a consistent and reproducible thaw profile and endpoint to each vial, thus providing a standardized thawing process, eliminating variability that could have a detrimental effect on the safety and efficacy of the cell therapy, and providing a significant reduction in cell handling risk in a clinical setting. The new ThawSTAR automated cell thawing system that will be developed as a result of this collaboration is an expansion of BioCision’s technology platform and will be made available commercially. BioCision is also developing other vial formats to address the needs of the larger cell therapy market.

Similar Private Companies By Industry

Company Name Region
Biostar Inc. United States
Solarant Medical, Inc. United States, Inc. United States
MyoStim Inc. United States
Artromick International, Inc. United States

Recent Private Companies Transactions

Private Placement
December 22, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BioCision, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at